tion by TCD does not necessarily imply the presence of a PFO. Any right-to-left shunt such
as that resulting from ventricular septal defect or intrapulmonary shunt may result in the …

This chapter about treatment and prevention of stroke is part of the 7th ACCP Conference on
Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 …

Task Force members, Chairperson, John Deanfield*, Erik Thaulow, Carol Warnes, Gary
Webb, Frantizek Kolbel, Andreas Hoffman, Keld Sorenson, Harald Kaemmerer, Ulf Thilen …

Background: The optimal strategy to prevent recurrent presumed paradoxical emboli in
patients with patent foramen ovale is unknown. Purpose: To synthesize the current …

This article about treatment and prevention of stroke is part of the Antithrombotic and
Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical …

Background Device closure of atrial septal defect (ASD) and patent foramen ovale (PFO) are
both associated with short‐and long‐term complications. Our knowledge of the complication …

Background and Purpose—Patients discovered to have a patent foramen ovale in the
setting of a cryptogenic stroke may be treated with percutaneous closure, antiplatelet …

We have conducted a systematic review of air embolism complications of neurosurgery in
the sitting position and patent foramen ovale (PFO) closure. It assesses the risk and benefit …

(PFO) appears to carry no physiologic or survival benefit for normal individuals. In states of
abnormal right sided cardiac or pulmonary vascular capacitance or resistance, PFO has …

Background and Purpose—Transcatheter closure of patent foramen ovale (PFO) is
increasingly being performed and monitored with transthoracic or transesophageal …